跳至主要内容
临床试验/NCT04441333
NCT04441333已完成不适用

Usability, Safety and Efficacy of AspivixTM, an Atraumatic Innovative Uterine Cervical Traction Device: a Pilot Phase Followed by a Comparative Study (Pilot)

Aspivix SA2 个研究点 分布在 1 个国家目标入组 13 人开始时间: 2020年7月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
13
试验地点
2
主要终点
Usability and efficacy from the practitioner's perspective: questionnaire

研究概览

简要总结

Limited mobility of the uterine cervix and alignment with the vaginal canal is often required during insertion of an intrauterine contraceptive device (IUD). Currently, the available instruments are traumatic tenacula, which could cause pain and bleeding and therefore represent an obstacle for certain patients to pursue their medical follow-up.

AspivixTM is a new device, which enables atraumatic traction of the cervix while respecting its specific semi-circular anatomic shape through a system powered by a vacuum chamber.

The aim of our pilot study is to assess the usability, safety and efficacy of the device.

Note: Study is made of 2 phases (pilot phase followed by a comparative phase). Details regarding comparative study is registered separately.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Participants older than 18 years
  • Participants presenting at the outpatient clinic for Mirena IUD insertion.
  • Participants able to provide informed consent as documented by signature with at least 24 hours of reflection time
  • Good understanding of written and oral speaking used at the centre where the study will be carried out.

排除标准

  • Participants who are contraindicated for the insertion of the IUD Mirena
  • Participants under use of excessive alcohol, narcotics or benzodiazepines prior to procedure
  • Participants who do not wish to be informed of a chance discovery
  • Participant receiving anaesthetics prior to IUD insertion procedure
  • Participants on anticoagulant medication
  • Participants under use of an analgesic
  • Previous cervical operation
  • Severe vaginal bleeding
  • Participant previously enrolled in this study
  • Cervix diameter smaller than 26 mm
  • Mullerian anomalies with two cervices
  • Nabothian cyst
  • Cervical myomas
  • Cervical condylomas
  • Squamous intraepithelial lesion (Cervical dysplasia)
  • Cervical endometriosis
  • Cervical tears
  • A well exposed cervix and / or well aligned vaginal and cervical canals where no traction is required for IUD insertion
  • Other cervical abnormalities (cervical polyp, cervical lesion, or irregularity) which may contraindicate or complicate IUD insertion
  • Large ectopy, for which it is not possible to find a suitable location near the ectopy where native tissue is present
  • Large scar tissue, for which it is not possible to find a suitable location near the scar where native tissue is present

结局指标

主要结局

Usability and efficacy from the practitioner's perspective: questionnaire

时间窗: Right after the use of the device (right after the end of the procedure to insert the IUD).

The practitioner will assess the usability and efficacy of the Investigational Device using a 5 point Likert 'Usability and Efficacy Questionnaire'.

次要结局

  • Participant's reported pain: Visual Analogue Scale(Before the procedure, during speculum insertion, during AspivixTM vacuum application, during application of cervical traction, during IUD insertion, during AspivixTM release, 5 minutes after the end of the procedure)
  • Assessment of patient's satisfaction: questionnaire(Right after the use of the device (right after the end of the procedure to insert the IUD).)
  • The number of placement attempts before traction can be applied(During the procedure to insert the IUD which should last less than 5 minutes.)
  • The number of spontaneous releases during traction(During the procedure to insert the IUD which should last less than 5 minutes.)
  • Assessment of bleeding(During the procedure to insert the IUD which should last less than 5 minutes.)
  • Assessment of adverse events(During the procedure to insert the IUD which should last less than 5 minutes.)
  • Assessment of device deficiencies(During the procedure to insert the IUD which should last less than 5 minutes.)
  • Identification of new risks(During the procedure to insert the IUD which should last less than 5 minutes.)

研究者

发起方
Aspivix SA
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验